| Species |
Human |
| Protein Construction |
IL-17A/CTLA-8 (Gly24-Ala155)
Accession # Q16552-1 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized IL-17A/CTLA-8, His, Human at 1μg/ml (100μl/well) on the plate can bind Human IL17R alpha, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
16.2 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 15-20 kDa and 25-30 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Interleukin‑17A (IL‑17A), also known as CTLA‑8, is a 15‑20 kDa glycosylated cytokine that plays an important role in anti‑microbial and chronic inflammation. The six IL‑17 cytokines (IL‑17A‑F) are encoded by separate genes but adopt a conserved cystine knot fold.IL-17A is a ligand for IL17RA and IL17RC. The heterodimer formed by IL17A and IL17F is a ligand for the heterodimeric complex formed by IL17RA and IL17RC. Involved in inducing stromal cells to produce proinflammatory and hematopoietic cytokines. |
| Synonyms |
CTLA-8; IL17; IL17A; IL-17CTLA-8; interleukin 17A |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
